Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ILMN
176.28
+2.52 (1.45%)
Real-time:   3:29PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 173.80 - 177.14
52 week 119.37 - 189.48
Open 174.01
Vol / Avg. 703,125.00/1.10M
Mkt cap 25.68B
P/E 35.13
Div/yield     -
EPS 5.02
Shares 146.00M
Beta 0.77
Inst. own 96%
Jul 24, 2017
Q2 2017 Illumina Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 30, 2017
Illumina Inc Annual Shareholders Meeting - 5:00PM EDT - Add to calendar
May 18, 2017
Illumina Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
Apr 25, 2017
Q1 2017 Illumina Inc Earnings Call - Webcast
Apr 25, 2017
Q1 2017 Illumina Inc Earnings Release
Mar 7, 2017
Illumina Inc at Cowen Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '17) 2017
Net profit margin 58.19% 17.85%
Operating margin 8.70% 24.48%
EBITD margin - 29.68%
Return on average assets 31.44% 10.74%
Return on average equity 62.00% 22.87%
Employees 5,500 -
CDP Score - -

Address

5200 Illumina Way
SAN DIEGO, CA 92122-4616
United States - Map
+1-858-2024500 (Phone)
+1-858-2024766 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Officers and directors

Jay T. Flatley Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Francis A. deSouza President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Sam Samad Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Marc A. Stapley Executive Vice President, Chief Administrative Officer
Age: 46
Bio & Compensation  - Reuters
Garret Hampton Ph.D. Executive Vice President - Clinical Genomics
Age: 51
Bio & Compensation  - Reuters
Omead Ostadan Executive Vice President - Operations, Products and Strategy
Age: 45
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Arthur Blaine Bowman Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Caroline D. Dorsa Director
Age: 57
Bio & Compensation  - Reuters